eli lilly and company - Search News

News

Eli Lilly Vows to Make Weight-Loss Pill in U.S.

The Motley Fool on MSN · 17h

Where Will Eli Lilly Be in 5 Years?

Continue » The leader in diabetes and obesity Despite Lilly's huge success in treating diabetes and obesity, it's not the leader in those markets. That honor belongs to Novo Nordisk (NYSE: NVO), which sells the blockbuster drugs Ozempic and Wegovy for treating diabetes and obesity,

The New York Times · 1d

What to Know About Eli Lilly’s Daily Pill for Weight Loss

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes.

New York Post · 9h

Everything to know about the new weight loss pill that works as well as Ozempic — and when you can get it

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, stab-free way to treat diabetes and obesity.

1d

Why It Makes Sense To Buy Eli Lilly Stock At $840

The trial met its primary objectives, showing the pill’s effectiveness in helping patients with Type 2 diabetes achieve ...

10hon MSN

Eli Lilly Vows to Make Weight-Loss Pill in U.S. as Trump Pushes for Domestic Manufacturing

Eli Lilly plans to make its experimental drug orforglipron in the U.S. after it secures regulatory approval, says CEO Dave ...

4hon MSN

The Score: UnitedHealth, Netflix, Eli Lilly and More Stocks That Defined the Week

Pharmaceutical companies—including Eli Lilly and Novo Nordisk, which currently dominate the obesity market—have been testing ...

1don MSN

Eli Lilly says GLP-1 pill for diabetes and weight loss effective in study, plans to seek FDA approval

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

1don MSN

Experimental GLP-1 pill helped people with diabetes lose weight and lower blood sugar, Eli Lilly says

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

1d

Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron's Promising Phase 3 Results

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

1d

UnitedHealth tumbles, Eli Lilly climbs, TSMC holds outlook

On today's Market Minute, Madison Mills takes a closer look at the top stories on Wall Street. UnitedHealth Group (UNH) stock ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results